AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
IPO Year: 2010
Exchange: NASDAQ
Website: aveooncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2022 | $15.00 | Buy → Hold | Stifel |
| 7/12/2021 | $27.00 → $19.00 | Buy | HC Wainwright & Co. |
The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors. The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI. Keynote speakers include: Steve Kraus, Partner at Bessemer Venture Partners and world-renown
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a fully diluted basis. "We are excited to complete LG Chem's acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world's leading oncology companies with a robust clinical pipeline of innovative therapies," said Shin Hak-Cheol, Chief Execu
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction. "Today's approval is a significant step toward the c
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO's Special Meeting of Stockholders (the "Special Meeting") "FOR" the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). Subject to the terms and conditions of the merger agreement, including obtaining requisite AVEO stockholder approval at the Special Meeting, LG Chem will acquire AVEO for merger consideration of $15.00 per share i
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ritchie Bros. Auctioneers Incorporated (NYSE:RBA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of IAA, Inc. to RBA for $10.00 per share in cash and 0.5804 shares of RBA common stock for each share of IAA common stock. If you are an RBA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected]. Akouos, Inc. (NASDAQ:AKUS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect
– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights At September 30, 2022, AVEO r
Acquisition Provides LG Chem's Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem's Efforts to Deliver Continued Growth AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of Patients with CancerAVEO to Establish and Operate as the U.S. Commercial Foundation for LG Chem Life Sciences' Oncology SegmentTransaction Price Represents a 43% Premium to AVEO's Closing Price on October 17, 2022 SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) and AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercia
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office ("USPTO") has allowed U.S. Patent Application No. 17/720,619, titled "Use of Tivozanib to Treat Subjects with Refractory Cancer" (the "Application"). AVEO expects to receive a Notice of Allowance for this Application. This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference. The panel titled "Building Combinations: What are the Novel Ideas?" will be held on Wednesday, September 28th, at 10:40 a.m. eastern time. If you are interested in arranging a 1x1 meeting at the conference, please contact your Cantor representative. For more details, please see the Calendar of Events sec
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September, including: 2022 Wells Fargo Healthcare ConferenceDate:Wednesday - Friday, September 7th - 9thFormat:1x1 Investor Meetings H.C. Wainwright 24th Annual Global Investment ConferenceDate:Monday, September 12th at 5:00 p.m. Eastern TimeFormat:Fireside Chat and 1x1 Investor MeetingsDetails:A live webcast of the H.C. Wainwright fireside chat can be
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)
Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity
Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity
Stifel downgraded AVEO Oncology from Buy to Hold and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of AVEO Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $27.00 previously
SVB Leerink reiterated coverage of AVEO Pharmaceuticals with a rating of Outperform and set a new price target of $18.00 from $10.00 previously
SVB Leerink resumed coverage of AVEO Pharmaceuticals with a rating of Buy
SC 13D/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)
SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)
SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)
SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)
SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)
15-12G - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
POS AM - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
POS AM - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
POS AM - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
S-8 POS - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
S-8 POS - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
S-8 POS - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)
- Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience - AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company's organizational efficiency and advancing its pipeline of products. "We are excited to welcome Jeb to the team during an important phase of AVEO's evolution as an integrated clinical development and commercial organization," said Michael Bailey, president and chief executive officer of AVEO. "With a successful
AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company's Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. "Dr. Cullen, among the leading voices in cancer research and treatment, has made many important contributions to the evolving tre
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration’s (FDA) recent approval of FOTIVDA marks a transformative event for AVEO, and we are eager to demonstrate FOTIVDA’s potential to serve as a meaningful new treatment option within the growing relapsed or refractory advanced renal cell carcinoma (RCC) patient population. We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month,” said Michael Bailey, president and chief executive officer of AVEO. “In parallel, we remain focused on the evalua
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA® (tivozanib). FOTIVDA is AVEO’s differentiated oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. “Directly on the heels of FOTIVDA’s approval, it is a pleasure to announce Mike’s appointment to chief co
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead of the potential U.S. launch of tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC), including the addition of Dr. Corinne Epperly to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “If approved, we believe tivozanib has the potential to serve as a new treatment for the rapidly growing population of patients with relapsed or refractory RCC. In support of the further clinical and commercial development of tivozanib, we have
– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights At September 30, 2022, AVEO r
Acquisition Provides LG Chem's Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem's Efforts to Deliver Continued Growth AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of Patients with CancerAVEO to Establish and Operate as the U.S. Commercial Foundation for LG Chem Life Sciences' Oncology SegmentTransaction Price Represents a 43% Premium to AVEO's Closing Price on October 17, 2022 SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) and AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercia
– Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call today at 4:30 p.m. ET – BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO's management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 4, 2022, to discuss the financial results and provide a business update. The call can be accessed by dialing (877) 423-9813 (U.S. and Canada) or (201) 689-8573 (international). The passcode for the conference call is 13730553. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the In
– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Company to Host Conference Call Today at 8:30 a.m. ET – BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2022. "We recently celebrated the one-year anniversary of our U.S. commercial launch of FOTIVDA® (tivozanib). During the first quarter
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and provide a business update. The call can be accessed by dialing (800) 954-1051 (U.S. and Canada) or (303) 223-0117 (international). The passcode for the conference call is 22018215. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Invest
– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescriptions Filled Compared to 3Q 2021 – – Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million – – Long-term data from pivotal TIVO-3 study presented at ASCO GU 2022 continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA – – Company to Host Conference Call Today at 8:30 a.m. ET – BOSTON, March 14, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2022, to discuss the financial results and provide a business update. The call can be accessed by dialing (877) 423-9813 (U.S. and Canada) or (201) 689-8573 (international). The passcode for the conference call is 13727273. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Inve
– Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $14.3 Million – – Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) – – Ficlatuzumab and ERBITUX® (cetuximab) Granted Fast Track Designation by the U.S. FDA for R/R HNSCC; Potential Registrational Clinical Trial Expected to Commence in 1H 2023 – – Company to Host Conference Call Today at 4:30 p.m. ET – AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. "During the thi
AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business update. The call can be accessed by dialing (844) 882-7841 (U.S. and Canada) or (574) 990-9828 (international). The passcode for the conference call is 1647457. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Investors section of the AVEO website at www.av
On January 17, 2023, the parties received written notice from CFIUS that it had determined that there were no unresolved national security concerns regarding the transaction and that it had concluded action under Section 721 of the Defense Production Act of 1950, as amended, thereby clearing the transaction contemplated by the Merger Agreement. All required regulatory approvals to complete the Merger have now been received. The closing of the Merger is expected to occur on January 19, 2023, subject to the satisfaction or waiver of the remaining customary closing conditions set forth in the Merger Agreement that by their nature are to be satisfied at the closing of the Merger.
As previously disclosed, on October 18, 2022, AVEO Pharmaceuticals, Inc., a Delaware corporation (“AVEO”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with LG Chem, Ltd., a corporation organized and existing under the laws of the Republic of Korea (“LG Chem”), and Acacia Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of LG Chem (“Merger Sub”), pursuant to and subject to the terms and conditions of which Merger Sub will be merged with and into AVEO, with AVEO surviving the merger as an indirect wholly owned subsidiary of LG Chem (the “Merger”). Also as previously disclosed, on December 1, 2022, each of AVEO and LG Chem received a notice
AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction. "Today's approval is a significant step toward the completion of AVEO's transaction with LG Chem
-SEC Filing
https://www.scribd.com/document/609450380/Aveo-Patent
Upgrades For SolarEdge Technologies Inc (NASDAQ:SEDG), Northland Capital Markets upgraded the previous rating of Underperform to Market Perform. In the third quarter, SolarEdge Technologies showed an EPS of $0.91, compared to $1.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of $375.90 and a 52-week-low of $190.15. SolarEdge Technologies closed at $211.30 at the end of the last trading period. According to Scotiabank, the prior rating for Delek US Holdings Inc (NYSE:DK) was changed from Sector Underperform to Sector Perform. Delek US Hldgs earned $0.02 in the third quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $35.23 and a
Within the last quarter, AVEO Pharmaceuticals (NASDAQ:AVEO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 3 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, AVEO Pharmaceuticals has an average price target of $15.0 with a high of $15.00 and a low of $15.00. Below is a summary of how these 4 analysts rated AVEO Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more neg
Stifel analyst Stephen Willey downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Hold and announces $15 price target.
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.18) by 50 percent. This is a 70 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $30.45 million which beat the analyst consensus estimate of $29.55 million by 3.04 percent. This is a 100.68 percent increase over sales of $15.17 million the same period last year.
JonesTrading analyst Soumit Roy downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Buy to Hold and announces $15 price target.